Product Information
Registration Status: ActiveFAKTU SUPPOSITORY is approved to be sold in Singapore with effective from 1988-04-26. It is marketed by TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE LTD, with the registration number of SIN00400P.
This product contains Cinchocaine 2.5mg, and Policresulen 100mg in the form of SUPPOSITORY. It is approved for RECTAL use.
This product is manufactured by Takeda GmbH
Amcapharm Pharmaceutical GmbH in GERMANY.
It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.
Description
A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Indication
For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
Mechanism of Action
Local anesthetics block both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions through sodium channel inhibition. This reversibly stabilizes the membrane and inhibits depolarization, resulting in the failure of a propagated action potential and subsequent conduction blockade.
Pharmacokinetics
- Absorption
- In general, ionized forms (salts) of local anesthetics are not readily absorbed through intact skin. However, both nonionized (bases) and ionized forms of local anesthetics are readily absorbed through traumatized or abraded skin into the systemic circulation.
- Distribution
- Metabolism
- Primarily hepatic.
- Elimination
Toxicity
Subcutaneous LD50 in rat is 27 mg/kg. Symptoms of overdose include convulsions, hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest.
Active Ingredient/Synonyms
2-Butoxy-N-(2-(diethylamino)ethyl)cinchoninamide | 2-Butoxy-N-(alpha-diethylaminoethyl)cinchoninamide | 2-Butoxy-N-(beta-diethylaminoethyl)cinchoninamide | 2-Butoxy-N-[2-(diethylamino)ethyl]-4-quinolinecarboxamide | 2-Butoxy-quinoline-4-carboxylic acid (2-diethylamino-ethyl)-amide | 2-Butoxyquinoline-4-carboxylic acid diethylaminoethylamide | 2-N-Butoxy-N-(2-diethylaminoethyl)cinchoninamide | alpha-Butyloxycinchonic acid-gamma-diethylethylenediamine | alpha-Butyloxycinchoninic acid diethylethylenediamide | CINCHOCAINE | Cinchocainum | Cincocainio | Dibucaine | Dibucaine base | N-(2-(Diethylamino)ethyl)-2-butoxycinchoninamide | Cinchocaine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Active Ingredient/Synonyms
Policresulen | Policresulen |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.